COMBINED THERAPY WITH ARBEKACIN AND FOSFOMYCIN FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS

• Published in: Japanese journal of antibiotics Vol. 47; no. 6; pp. 798 - 803
• Main Authors: KONO, KENJI, TAKEDA, SEIJI, TATARA, ICHIRO, ARAKAWA, KIKUO, TANAKA, HIROAKI, MIYAKE, SHUNJI, MINAMIKAWA, HIROMICHI, HOSHINO, HIROSUKE, SATO, MIKIO, HATTORI, FUMITADA, KAWAHIRA, KOZABURO
• Format: Journal Article
• Language: English
• Published: Japan Japan Antibiotics Research Association 01.06.1994
• Subjects: Aminoglycosides; Anti-Bacterial Agents; Dibekacin - analogs & derivatives; Dibekacin - therapeutic use; Drug Therapy, Combination - therapeutic use; Fosfomycin - pharmacology; Fosfomycin - therapeutic use; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Pseudomonas aeruginosa - drug effects; Pseudomonas Infections - complications; Pseudomonas Infections - drug therapy; Staphylococcal Infections - complications; Staphylococcal Infections - drug therapy; Staphylococcus aureus - drug effects; Superinfection - drug therapy
• ISSN: 0368-2781; 2186-5477
• DOI: 10.11553/antibiotics1968b.47.798

We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination ofarbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy. This combination thus appeared to be an effective regimen for the treatment of MRSA infections. However, its bacteriological efficacy against concomitant Pseudomonas aeruginosa strains was only 16.7% (1/6). In addition, in 4 episodes of superinfection involving P. aeruginosa strains developed during the combination therapy.